Bladder EpiCheck® Included in 2022 European Association of Urology (EAU) Clinical Guidelines on Non-Muscle Invasive Bladder Cancer (NMIBC) Clinical Guidelines Support Adoption of Urinary Biomarker Tests with High Sensitivity and Negative Predictive Values for High-Grade Disease to Replace and/or Postpone Cystoscopies in Low- and Intermediate-Risk NMIBC Publication of Meta-Analysis in European Urology Oncology Showed Bladder EpiCheck has Best Performance Amongst Guideline-Recommended Urinary Biomarker Tests
SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced its Bladder EpiCheck® test has been included in the 2022 European Association of Urology (EAU) Clinical Guidelines for non-muscle invasive bladder cancer (NMIBC). The EAU guidelines aim to provide practical recommendations on the clinical management of NMIBC, to assist physicians in making informed treatment decisions with available scientific data.
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.